How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Red Blood Cell Count Test Market
- By Test Type: Complete Blood Count (CBC) with RBC, Automated RBC Count, Manual RBC Count, Reticulocyte Count, Hemoglobin Concentration Test
- By End User: Hospitals, Diagnostic Laboratories, Clinics, Blood Banks, Research Laboratories
- By Sample Type: Venous Blood, Capillary Blood, Arterial Blood
- By Technology: Flow Cytometry, Electrical Impedance, Spectrophotometry, Image Analysis
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Complete Blood Count (CBC) with RBC leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 272 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.165 →
- 11 Company Profiles 14 players: SWOT & benchmarking p.173 →
Full report · locked preview
Everything inside the Red Blood Cell Count Test Market report
A complete, evidence-based study - 11 chapters and 114 sections covering market size, segmentation across 4 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Test Type 5
End User 5
Sample Type 3
Technology 4
Companies profiled
Abbott Laboratories
Siemens Healthineers
Sysmex Corporation
Beckman Coulter (Danaher Corporation)
Bio-Rad Laboratories
Horiba Ltd.
Mindray Medical International Limited
F. Hoffmann-La Roche AG
Becton
Dickinson and Company (BD)
Thermo Fisher Scientific
Ortho Clinical Diagnostics
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sysmex Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Beckman Coulter (Danaher Corporation)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Horiba Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Mindray Medical International Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →F. Hoffmann-La Roche AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Becton
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Thermo Fisher Scientific
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Ortho Clinical Diagnostics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →BioMérieux
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Nova Biomedical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,529M by 2033 · 6.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Complete Blood Count (CBC) with RBC46.8
- Automated RBC Count10.1
- Manual RBC Count14.6
- Reticulocyte Count10.1
- Hemoglobin Concentration Test18.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,339M → $2,396M · 7.5%
Europe$933.0M → $1,498M · 6.1%
Asia Pacific$851.9M → $1,352M · 5.9%
Latin America$527.3M → $810.4M · 5.5%
Middle East and Africa$405.7M → $598.1M · 5.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.072026
6.102027
6.102028
6.122029
6.132030
6.132031
6.152032
6.172033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories15.3
- Siemens Healthineers19.9
- Sysmex Corporation6.1
- Beckman Coulter (Danaher Corporation)14.3
- Bio-Rad Laboratories9.1
- Horiba Ltd.7.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type25.7%
End User16.8%
Sample Type37.3%
Technology20.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.0
- Europe22.5
- Asia Pacific20.3
- Latin America12.2
- Middle East and Africa9.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 95 | 90 | 92 | 98 | 85 | 84 | 91 |
| Siemens Healthineers | 84 | 81 | 92 | 88 | 76 | 92 | 86 |
| Sysmex Corporation | 79 | 67 | 63 | 87 | 63 | 84 | 74 |
| Beckman Coulter (Danaher Corporation) | 78 | 61 | 61 | 80 | 81 | 58 | 70 |
| Bio-Rad Laboratories | 51 | 55 | 76 | 64 | 61 | 73 | 63 |
| Horiba Ltd. | 62 | 64 | 57 | 62 | 51 | 48 | 57 |
| Mindray Medical International Limited | 64 | 60 | 49 | 58 | 54 | 51 | 56 |
| F. Hoffmann-La Roche AG | 49 | 37 | 55 | 58 | 37 | 57 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Siemens Healthineers
- Sysmex Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Siemens Healthineers | ✓ | ◐ | ✓ | ◐ | ✓ | ✓ |
| Sysmex Corporation | ◐ | ◐ | − | ✓ | ◐ | ✓ |
| Beckman Coulter (Danaher Corporation) | ◐ | − | − | ◐ | ✓ | ◐ |
| Bio-Rad Laboratories | − | ◐ | ◐ | − | ◐ | ✓ |
| Horiba Ltd. | − | − | − | − | ◐ | − |
| Mindray Medical International Limited | ◐ | − | − | − | ◐ | ◐ |
| F. Hoffmann-La Roche AG | ◐ | − | − | ◐ | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories91
2Siemens Healthineers86
3Sysmex Corporation74
4Beckman Coulter (Danaher Corporation)70
5Bio-Rad Laboratories63
6Horiba Ltd.57
7Mindray Medical International Limited56
8F. Hoffmann-La Roche AG49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Abbott LaboratoriesSiemens Healthineers
Challenger2
Strong scale, closing on the leaders.
Sysmex CorporationBeckman Coulter (Danaher Corporation)
Contender2
Focused players with pockets of strength.
Bio-Rad LaboratoriesHoriba Ltd.
Niche2
Specialists in a single segment or region.
Mindray Medical International LimitedF. Hoffmann-La Roche AG
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Red Blood Cell Count Test Market — a $335M beachhead inside a $5.76B market.
Beachhead (SOM)$335Mobtainable near-term
Serviceable (SAM)$2.26Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Complete Blood Count (CBC) with RBC
Best fit — highest urgency & budget in Test Type.
Economic buyer80 fit
Automated RBC Count
Strong fit — clear ROI and a fast path to value.
End user64 fit
Manual RBC Count
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Sample Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Red Blood Cell Count Test Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified22%
Evaluation15%
Closed-won7%
$10.9KCAC
$58KLTV
5.3:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Red Blood Cell Count Test Market is a durable-growth opportunity — $8.86B by 2033, compounding at 7.8%.
TAM · 2025$4.84Btoday
TAM · 2033$8.86Bforecast
CAGR7.8%2027–2033
Cumulative$60.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.86BTotal addressable market
SAM$3.33BServiceable available market
SOM$550MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.8% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.86BLarge & growingTAM by 2033 at 7.8% CAGR
$3.33BServiceable nowreachable with today’s model
$550MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.91BBear5.1% CAGR
$8.86BBase7.8% CAGR
$11.3BBull10.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Red Blood Cell Count Test Market — a $6.76B market by 2033. Plan: grow share from 8.5% to 17.9%.
Market size · 2033$6.76Btotal addressable
Market CAGR4.7%2027–2033
Target share17.9%from 8.5% today
Revenue ambition$1.21Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.5% | 17.9% | Ahead |
| Revenue | $603M | $1.21B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 35.7% | 40.2% | Behind |
| Customer retention | 91.4% | 92.2% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $133M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Red Blood Cell Count Test Market conversation — a $8.41B market you can size, segment and defend in minutes.
Market size · 2033$8.41Btotal opportunity
Growth11.1%CAGR to 2033
Addressable buyers1,610+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 4 mopayback period
$91K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Abbott LaboratoriesSiemens HealthineersSysmex CorporationBeckman Coulter (Danaher Corporation)Bio-Rad LaboratoriesHoriba Ltd.Mindray Medical International LimitedF. Hoffmann-La Roche AG+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Red Blood Cell Count Test Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Red Blood Cell Count Test Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Red and Blue Light Therapy Device Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportRecyclable Protective Mask Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportRecto-vaginal Fistula Treatment Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportRectovaginal Fistula Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportRectopexy Mesh and Graft Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportRectocele Treatment Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportRectangular Water Bath Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportRectal Tube Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportRectal Syringes Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportRectal Retractor Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportRectal Mesalazine Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportRectal Manometry Catheter Market
Market size, share, segmentation and regional forecast.
$718M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.